3-Bromopyruvic acid

3-Bromopyruvic acid

Catalog Number:
L002372677APE
Mfr. No.:
APE-B7922
Price:
$180
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          3-Bromopyruvic acid (3-BP) is a hexokinase II inhibitor with Ki of 2.4 mM, is an effective antitumor agent on the hepatoma cells[1].
          3-BP decreases proliferation of hepatocellular carcinoma BEL-7402 cells that express hexokinase II, an isoform of hexokinase overexpressed in many cancers[2,3].
          3-BP reduces tumor growth and induces tumor necrosis in a hepatocellular carcinoma mouse xenograft model when administered at a dose of 50 mg/kg per day, six days per week, for three weeks[2].

          [1]. Ihrlund L S, Hernlund E, Khan O, et al. 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Molecular Oncology, 2008, 2(1): 94-101.
          [2]. Gong L, Wei Y, Yu X, et al. 3-Bromopyruvic acid, a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells: In vitro and in vivo findings. Anticancer Agents Med. Chem, 2014, 14(5): 771-776.
          [3]. Lis P, Dylag M, Niedźwiecka K, et al. The HK2 dependent "Warburg Effect" and mitochondrial oxidative phosphorylation in cancer: Targets for effective therapy with 3-bromopyruvate. Molecules, 2016, 21(12): E1730.

      • Properties
        • Alternative Name
          Bromopyruvic acid; Hexokinase II Inhibitor II, 3-BP; 3-bromo-2-oxopropanoic acid
          CAS Number
          1113-59-3
          Molecular Formula
          C3H3BrO3
          Molecular Weight
          166.96
          Appearance
          A solid
          Purity
          98.00%
          Solubility
          ≥16.7 mg/mL in H2O; ≥23.55 mg/mL in DMSO; ≥49.5 mg/mL in EtOH
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Michaela T. Reichmann, Liku B Tezera, et al. "Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets." J Clin Invest. 2021 Aug 2;131(15):e148136. PMID:34128839

    We Also Recommend

    OSMI-1

    $372

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.